---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-045937"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T02:56:41.686657+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# ANI Pharmaceuticals supplements proxy statement on stock plan share reserve

## Summary
- As of March 24, 2025, total stock options outstanding: 571,880 (weighted avg exercise price $46.28, remaining term 3.68 yrs).
- Performance/restricted stock awards: 1,866,153 shares; shares available for future grant: 1,177,800.
- Inducement grants (non-shareholder approved) comprise 184,989 options at avg exercise price $29.63, term 5.57 yrs.
- Company seeks approval of Amended and Restated 2022 Stock Incentive Plan; no changes to other proposals or meeting date.

## SEC filing metadata
- accession: 0001104659-25-045937
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000110465925045937/0001104659-25-045937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000110465925045937/tm2514446d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-045937
- JSON: https://secwatch.observer/filing/0001104659-25-045937.json
- Plain text: https://secwatch.observer/filing/0001104659-25-045937.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.